» Articles » PMID: 17090705

An Opioid Agonist That Does Not Induce Mu-opioid Receptor--arrestin Interactions or Receptor Internalization

Overview
Journal Mol Pharmacol
Date 2006 Nov 9
PMID 17090705
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

G protein-coupled receptor desensitization and trafficking are important regulators of opioid receptor signaling that can dictate overall drug responsiveness in vivo. Furthermore, different mu-opioid receptor (muOR) ligands can lead to varying degrees of receptor regulation, presumably because of distinct structural conformations conferred by agonist binding. For example, morphine binding produces a muOR with low affinity for beta-arrestin proteins and limited receptor internalization, whereas enkephalin analogs promote robust trafficking of both beta-arrestins and the receptors. Here, we evaluate muOR trafficking in response to activation by a novel mu-selective agonist derived from the naturally occurring plant product, salvinorin A. It is interesting that this compound, termed herkinorin, does not promote the recruitment of beta-arrestin-2 to the muOR and does not lead to receptor internalization. Moreover, whereas G protein-coupled receptor kinase overexpression can promote morphine-induced beta-arrestin interactions and muOR internalization, such manipulations do not promote herkinorin-induced trafficking. Studies in mice have shown that beta-arrestin-2 plays an important role in the development of morphine-induced tolerance, constipation, and respiratory depression. Therefore, drugs that can activate the receptor without recruiting the arrestins may be a promising step in the development of opiate analgesics that distinguish between agonist activity and receptor regulation and may ultimately lead to therapeutics designed to provide pain relief without the adverse side effects normally associated with the opiate narcotics.

Citing Articles

Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery.

Shen S, Wu C, Yang Z, Wang K, Shao Z, Yan W Acta Pharmacol Sin. 2025; .

PMID: 39910211 DOI: 10.1038/s41401-024-01472-9.


Chlorinated Enyne Fatty Acid Amides from a Marine Cyanobacterium: Discovery of Taveuniamides L-M and Pharmacological Characterization of Taveuniamide F as a GPCR Antagonist with CNR1 Selectivity.

Elsadek L, Ellis E, Seabra G, Paul V, Luesch H Mar Drugs. 2024; 22(1).

PMID: 38248654 PMC: 10817531. DOI: 10.3390/md22010028.


The opioid receptor: emergence through millennia of pharmaceutical sciences.

Fairbanks C, Peterson C Front Pain Res (Lausanne). 2023; 4:960389.

PMID: 38028425 PMC: 10646403. DOI: 10.3389/fpain.2023.960389.


From Plant to Chemistry: Sources of Active Opioid Antinociceptive Principles for Medicinal Chemistry and Drug Design.

Turnaturi R, Piana S, Spoto S, Costanzo G, Reina L, Pasquinucci L Molecules. 2023; 28(20).

PMID: 37894567 PMC: 10609244. DOI: 10.3390/molecules28207089.


A Route to Potent, Selective, and Biased Salvinorin Chemical Space.

Hill S, Dao N, Dang V, Stahl E, Bohn L, Shenvi R ACS Cent Sci. 2023; 9(8):1567-1574.

PMID: 37637743 PMC: 10450872. DOI: 10.1021/acscentsci.3c00616.


References
1.
Raehal K, Walker J, Bohn L . Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005; 314(3):1195-201. DOI: 10.1124/jpet.105.087254. View

2.
Keith D, Murray S, Zaki P, CHU P, Lissin D, Kang L . Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem. 1996; 271(32):19021-4. DOI: 10.1074/jbc.271.32.19021. View

3.
Raehal K, Bohn L . Mu opioid receptor regulation and opiate responsiveness. AAPS J. 2005; 7(3):E587-91. PMC: 2751262. DOI: 10.1208/aapsj070360. View

4.
Shenoy S, Drake M, Nelson C, Houtz D, Xiao K, Madabushi S . beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem. 2005; 281(2):1261-73. DOI: 10.1074/jbc.M506576200. View

5.
Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson C, Wang S . Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem. 2006; 281(16):10856-64. DOI: 10.1074/jbc.M513380200. View